Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?

被引:0
|
作者
Ishai A. [1 ]
Tawakol A. [1 ,2 ]
机构
[1] Cardiac MR PET CT Program, Department of Imaging, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
[2] Cardiology Division, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
关键词
Atherosclerosis; FDG-PET; Inflammation;
D O I
10.1007/s12170-015-0459-0
中图分类号
学科分类号
摘要
Atherosclerosis is a chronic inflammatory condition complicating cholesterol accumulation within the artery wall. Inflammation is believed to play an important role in the formation, progression, and ultimately the rupture of atherosclerotic plaques (the principle event leading to most myocardial infarctions and strokes). An enhanced understanding of the inflammatory process within the atheroma may therefore facilitate risk stratification and treatment strategies. Molecular imaging techniques such as PET/CT have the ability to quantify arterial inflammation and assess the high-risk features of atheromas thus may be useful for identifying patients who are at higher risk for an atherothrombotic event. In this review, we focus on the potential of FDG-PET/CT as a tool to measure arterial inflammation, enhance risk stratification, and to evaluate novel therapies directed against atherosclerotic disease. Additionally, this review will provide a discussion on current challenges as well as future directions. © 2015, Springer Science+Business Media New York.
引用
收藏
页码:1 / 8
页数:7
相关论文
共 50 条
  • [41] What do we know and what don't we know?
    Fawcett, J
    PSYCHIATRIC ANNALS, 2006, 36 (01) : 5 - 6
  • [42] Propofol and children - what we know and what we do not know
    Rigby-Jones, Ann E.
    Sneyd, J. Robert
    PEDIATRIC ANESTHESIA, 2011, 21 (03) : 247 - 254
  • [43] What we know and what we do not know about DMN
    Figl, Kathrin
    Mendling, Jan
    Tokdemir, Gul
    Vanthienen, Jan
    ENTERPRISE MODELLING AND INFORMATION SYSTEMS ARCHITECTURES-AN INTERNATIONAL JOURNAL, 2018, 13
  • [44] MYELIN VESICLES - WHAT WE KNOW AND WHAT WE DO NOT KNOW
    SEDZIK, J
    BLAUROCK, AE
    JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 41 (02) : 145 - 152
  • [45] Brain drain:: what we know and what we do not know
    Wachter, Bernd
    Formative Years of Scholars, 2006, 83 : 51 - 66
  • [46] Risk, pregnancy and childbirth: What do we currently know and what do we need to know? An editorial
    Coxon, Kirstie
    Scamell, Mandie
    Alaszewski, Andy
    HEALTH RISK & SOCIETY, 2012, 14 (06) : 503 - 510
  • [47] WHAT WE SHOULD KNOW IN RELATION TO WHAT WE DO KNOW
    Rice, Donald L.
    OCEANOGRAPHY, 2014, 27 (01) : 5 - 5
  • [48] Sleep and ADHD: what we know and what we do not know
    Cortese, Samuele
    SLEEP MEDICINE, 2015, 16 (01) : 5 - 6
  • [49] What we know and what to do
    Charlow, Nate
    SYNTHESE, 2013, 190 (12) : 2291 - 2323
  • [50] Voice tremor: what we know and what we do not know
    Gillivan-Murphy, Patricia
    Miller, Nick
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2011, 19 (03): : 155 - 159